Seroprevalence of cytomegalovirus antibodies in haemodialysis patients in
Morroco

Y. El Kamouni*, A. Allali, K. Dafir , L. Arsalane, S. Zouhair
Page No. 19-28

CMV infection is endemic in most countries of the world. It is likely to take severe forms in
immunocompromised individuals such as allograft recipients of marrow or organ, patients with
acquired immunodeficiency syndrome (AIDS) and hemodialysis patients, given that the
seroprevalence is high among the general population. Our study is a prospective description of the
seroprevalence of cytomegalovirus among chronic hemodialysis patients in Marrakech through a
serie of 500 patients treated in the hemodialysis centers of Marrakech, whose their serum is
analyzed in Virology department of the Military Hospital Avicenne , Marrakech teaching hospital,
over a period of 6 months, from September 2015 to March 2016. We collected demographycal,
clinical and biological data from the patients records and anamnesis. Serological test for the
presence of IgG and IgM anti CMV, was performed by immunoassay technique chemiluminescent
microparticle (CMIA), by ARCHITECT(ABBOTT DIAGNOSTIC). The prevalence of IgG and IgM
anti-CMV was 98% and 0.4% respectively. The mean age of patients with CMV IgG positive was
55.95 ± 14.21 years,which 50.2% are from low economic level . The mean hemodialysis duration
was 5.9 ± 5.1years among seropositive for CMV IgG, 63.2% of them are undergoing hemodialysis
three times a week. 298 (60.3%) patients with IgG anti CMV + were transfused at least once, all by
standard blood against 196 (39.7%) patients who have never been transfused. The mean recurrence
of blood transfusion is averaging 2.1transfusion.Among anti CMV IgG positive patients, 60.3% had
a surgical history against a single patient who has a history of transplantation. Clinically, one
patient is symptomatic. 11.9% and 1.4% of CMV seropositive patients have respectively a positive
HCV and HVB serology. Anemia was present in 387 (78.3%) of CMV + subjects , while the liver
function was normal in most patients. We recommend blood transfusion leukodepleted in the
hemodialysis population to reduce the risk of transfusion transmission CMV